Sponsor bankruptcy

The objective of this study is to obtain post-market clinical outcome data for the Algovita SCS System when used on-label, according to the applicable directions for use, using high fidelity tonic stimulation at either ultra-high pulse width or traditional pulse width for the treatment of persistent or recurrent back and/or leg pain following spinal surgery.

Inclusion Criteria:

• Patients with FBSS defined as persistent or recurrent back and/or leg pain despite one or more anatomically successful back surgeries for the same original pain.
• Age 18-75 years old at consent.
• Targeted pain intensity of ≥ 5 out of 10 on the Baseline visit NRS.
• ODI score of 41-80 out of 100 at the Baseline visit.
• Appropriate candidate for the surgical procedure and Algovita SCS therapy based on the clinical judgment of the investigator and the Algovita Instructions for Provider (IFP) in the Nuvectra product manuals.
• On stable pain medications for at least 28 days prior to consent. Stable is defined as no new or discontinued pain medications and no changes to total daily dose of any pain medications.
• Willing and capable of providing informed consent.
• Willing and able of complying with the study-related requirements, procedures, and visits.
• Speaks English as a primary language (as the Algovita patient manuals are only currently available in English).
• Has adequate cognitive ability to use the subject devices (e.g., PPC, PoP), as determined by the investigator.

Exclusion Criteria:

• Has a medical/psychological/psychiatric condition/disorder that could interfere with study procedures as determined by the investigator.
• Has a coexisting pain condition that might confound pain ratings, as determined by the investigator.
• Has a condition currently requiring or likely to require the use of MRI or diathermy.
• Has an existing drug pump, SCS System, or other active implantable device.
• Has any prior SCS experience.
• Pregnant or planning to become (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile, or be at least 2 years postmenopausal).
• For subjects with diabetes, HbA1c ≥ 8.5% as measured at the Baseline visit (or within the 3 months prior to the Baseline visit).
• Participating in another clinical trial that could affect the outcomes or requirements of this study as determined by the investigator.
• Involved in an injury claim under current litigation or have a pending or approved workers compensation claim.

Subjects who receive a permanent implant will be randomly assigned in a 1:1 ratio to one of the two sequences of treatment. Randomization schedules for each site will be prepared by the contract research organization (CRO) statistician and uploaded into a role-limited module of the study database. In order to avoid any potential bias, each site will designate an unblinded coordinator (UC). The UC, Nuvectra field personnel (FP) and the CRO will be unblinded to the treatment group. The participant and other site staff will be blinded to the treatment group.